
LeMaitre Vascular, Inc.
LMAT
Updated: 23/09/2026, 00:57:16
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
No summaries found.
- Share price
- $80.98
- Market cap
- $1.85B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- George W. LeMaitre
- Employees
- 651
- IPO date
- 19/10/2006
- Beta
- 0.493
- Last dividend
- $0.00
- Day range
- $79.83 – $81.32
- 52-week range
- $78.22 – $118.01
- 1-day performance
- 2.25%
- 1-year performance
- 3.53%
- Current drawdown (1Y)
- -31.38%
- CIK
- 0001158895
- CUSIP
- 525558201
- ISIN
- US5255582018
- Created
- 07/12/2025, 05:04:56
- Last update
- 23/09/2026, 00:57:16
Track LeMaitre Vascular, Inc. with an AI analyst
See which prediction-market events move LMAT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
Zacks Investment Research • STOCK • 25/05/2026, 15:46:08
LeMaitre to Participate at Upcoming Investor Conferences in June
GlobeNewsWire • STOCK • 20/05/2026, 18:25:00
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround
Zacks Investment Research • STOCK • 13/05/2026, 12:35:16
LeMaitre to Present at the Bank of America Healthcare Conference
GlobeNewsWire • STOCK • 07/05/2026, 19:15:00
3 Reasons Growth Investors Will Love LeMaitre (LMAT)
Zacks Investment Research • STOCK • 07/05/2026, 15:45:22
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 06/05/2026, 02:51:13
LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
Zacks Investment Research • STOCK • 05/05/2026, 21:10:50
LeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026
GlobeNewsWire • STOCK • 14/04/2026, 18:54:00
LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference
GlobeNewsWire • STOCK • 07/04/2026, 16:39:00
A LeMaitre Vascular (LMAT) Insider Sold 2,625 Shares for $285K
The Motley Fool • STOCK • 28/03/2026, 10:17:47
LeMaitre Vascular Up 30% as Insider Sells $285K in Stock. Here's What Investors Should Know
The Motley Fool • STOCK • 27/03/2026, 21:06:36
LeMaitre Vascular: The Compounder Keeps Compounding
Seeking Alpha • STOCK • 27/02/2026, 16:01:26